Twist Bioscience

Come see us at AACR! I won't be at the show personally, but I'm in town and happy to chat, plus we'll have a booth full of wonderful Twisters to connect with you onsite.

Christopher Conway (CEO Bio X Cell) and I met with our pharmaceutical partners in Japan and Korea this week to further strengthen engagement and deepen our relationships. #bioxcell #pharmapartnerships

AI will not transform drug discovery on its own. Data will. For years, we have generated predictions faster than we could validate them. The result is a growing gap between what we can design and what we can prove. That gap is now closing. Today, we are proud to partner with Amazon on the launch of Amazon Bio Discovery, a platform that connects AI-driven design directly to wet lab validation in a continuous loop. At Twist, we turn digital sequences into physical DNA that express proteins at scale, generating the experimental data that can make AI models smarter with every iteration. This is how discovery accelerates. In early work with Memorial Sloan Kettering, this approach enabled the design and testing of hundreds of thousands of antibody candidates in a fraction of the time it takes other workflows. More importantly, each cycle gets better. Better data leads to better models. Better models lead to better candidates. And better candidates lead to better therapies. This is the future of drug discovery. Connected. Iterative. Scalable. Twist is building it now.